読み込み中
NASDAQHealthcareBiotechnology
最新データ
$2.00
$0.00 · 0.00%
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
前日終値
$2.00
$0.00 · 0.00%
日中の時刻はETです。市場データは遅延する場合があります。
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
日中レンジ
現在 $2.00
52週レンジ
現在 $2.00
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
27
割高
センチメント
59
まちまち
リスク
66
高リスク
モメンタム
19
強い下落
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
日中レンジ
現在 $2.00
52週レンジ
現在 $2.00
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 |
|---|---|---|---|
| 研究開発 | 626.6万 USD | 281.1万 USD | 277.1万 USD |
| 販売・一般管理 | 155.5万 USD | 154.1万 USD | 101万 USD |
| 営業費用 | 782.1万 USD | 435.2万 USD | 378.1万 USD |
| 営業利益 | −782.1万 USD | −435.2万 USD | −378.1万 USD |
| 純利益 | −898.5万 USD | −3035.6万 USD | −377.9万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
